MRKR News

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology

Remix Therapeutics Appoints Mythili Koneru, MD, PhD, as Chief Medical Officer

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program